Regeneus Ltd

  • IPO date:
  • Sector: Healthcare
  • GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
  • Industry: Biotechnology
  • Company website

Company description

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.

Financial highlights

Market Capitalization$2.1451 million
P/E Ratio0
P/E Growth Ratio
Book Value0
Dividend Per Share0
Earnings Per Share-0.01
EBITDA-1,198.036
Profit Margin-1.6593
Operating Margin TTM-1.1847
Return on Assets TTM-0.3
Return on Equity TTM-3.552
Revenue TTM1,016.651

Income statement highlights

All numbers are in thousands

Date Total Revenue Cost of Revenue Gross Profit Total Operating Expenses
1999-06-30 158,297 93,324 64,973 116,731
2000-06-30 195,142 127,680 67,462 133,775
2001-06-30 206,411 151,786 54,625 168,208
2002-06-30 201,732 82,063 119,669 99,434
2010-06-30 575 114
2011-06-30 786 188
2012-06-30 1,186 245
2013-06-30 1,770 385
2014-06-30 998.036 621.498 376.538 12,848.503
2015-06-30 1,820.353 915.399 904.954 11,599.53
2016-06-30 1,735.462 291.743 1,443.719 8,237.692
2017-06-30 9,994.064 55.062 9,939.002 9,300.698
2018-06-30 575.406 0 575.406 8,241.954
2019-06-30 25.077 25.077 6,867.606
2020-06-30 1,663.345 1,663.345 5,013.856
2021-06-30 7,955.822 7,955.822 5,525.935
2022-06-30 0 4,650.116
2023-06-30

Balance sheet highlights

All numbers are in thousands

Date Cash Total Assets Total Liabilities Short Term Debt Long Term Debt Common Stock
1999-06-30 42,577 281,417 150,858 121,506 88,793 87,576
2000-06-30 39,104 289,365 128,271 41,764 25,058 83,670
2001-06-30 31,674 325,409 129,200 29,528 9,843 82,034
2002-06-30 33,483 50,204 9,666 30,762
2010-06-30 1,821 450 2,490
2013-06-30 14,175 16,733 1,029 24,978
2014-06-30 2,507.497 10,259.054 1,951.026 488.9 253 24,908.92
2015-06-30 3,012.812 9,579.261 1,307.127 253.37 31,076.819
2016-06-30 528.67 5,934.807 1,150.067 31,076.819
2017-06-30 4,135.136 9,164.81 1,064.902 0 31,076.819
2018-06-30 1,091.579 4,983.129 2,061.364 1,000 31,076.819
2019-06-30 255.463 2,541.814 8,928.309 3,780 31,076.819
2020-06-30 981.845 3,564.459 3,695.421 1,105.117 38,155.692
2021-06-30 3,792.695 5,260.343 2,850.282 5.296 1,528.21 38,286.543
2022-06-30 95.122 2,554.798 1,480.007 1,005.858 38,618.762
2023-06-30 302.792 714.484 2,529.442 1,947.015 38,618.762

Cash flow highlights

All numbers are in thousands

Date Net Income Total Cash Change in Cash Begin period cash End period cash Dividends
1999-06-30 15,030 33,427 18,712 9,998
2000-06-30 27,417 48,263 -1,088 3,160
2001-06-30 20,360 38,198 -8,584 3,160
2002-06-30 -83,194 5,426 9,682 7,113
2010-06-30
2011-06-30
2012-06-30
2013-06-30 410.658
2014-06-30 -7,523.218 -6,239.251 2,096.839 410.658 2,507.497
2015-06-30 -6,606.521 -5,923.36 505.315 2,507.497 3,012.812
2016-06-30 -3,573.873 -2,253.24 -2,484.142 3,012.812 528.67 0
2017-06-30 3,270.592 3,587.19 3,606.466 528.67 4,135.136 0
2018-06-30 -5,184.6 -4,247.04 -3,043.557 4,135.136 1,091.579
2019-06-30 -5,753.82 -3,608.496 -836.116 1,091.579 255.463
2020-06-30 -1,086.668 -1,917.586 726.382 255.463 981.845
2021-06-30 2,153.011 2,418.634 2,810.85 981.845 3,792.695
2022-06-30 -4,382.386 -4,357.426 -3,697.573 3,792.695 95.122
2023-06-30 -3,376.883 -659.66 207.667 95.122 302.789